Attruby cruises toward blockbuster land as BridgeBio CEO spots ‘stabilizer-first’ ATTR market

Despite their divergent second-quarter performance against consensus estimates, BridgeBio and Alnylam are now targeting the same population—first-line ATTR-CM patients—as the silencer-vs-stabilizer debate drags on.